Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96AG3
UPID:
S2546_HUMAN
Alternative names:
Solute carrier family 25 member 46
Alternative UPACC:
Q96AG3; A8K2F2; B3KRE6; B4DTA3; D3DSZ6; D6R9W7; Q04197
Background:
Mitochondrial outer membrane protein SLC25A46, also known as Solute carrier family 25 member 46, plays a pivotal role in mitochondrial organization. It is involved in the regulation of the MICOS complex, crucial for mitochondrial cristae biogenesis and dynamics, and interacts with the EMC to influence mitochondrial lipid homeostasis and fission.
Therapeutic significance:
SLC25A46 is linked to hereditary motor and sensory neuropathy 6B with optic atrophy and Pontocerebellar hypoplasia 1E, both severe neurological disorders. Understanding the role of SLC25A46 could open doors to potential therapeutic strategies for these conditions.